In this report, we present an update of the 2020 primary systematic review, to take into account more recent evidence on the efficacy, effectiveness and safety of newer and/or enhanced seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals aged 18 years and over.
Avian influenza viruses (AIV) remain prevalent among wild bird populations in the European Union and European Economic Area (EU/EEA), leading to significant illness in and death of birds.
Influenza is a disease of public health importance due to the substantial seasonal morbidity and mortality and the high pandemic potential of its aetiologic agents, influenza viruses.
Genetic and antigenic characterization data generated at the Worldwide Influenza Centre for viruses with collection dates after 31 January 2023 until 31 August 2023 informed the WHO influenza vaccine composition meeting (VCM) in September 2023 when recommendations were made for the southern hemisphere (SH) 2024 influenza season.
This document presents the core protocol for ECDC studies of CVE and IVE against symptomatic laboratory-confirmed influenza or SARS-CoV-2 infection, respectively, at primary care level.
This report provides an overview of highly pathogenic avian influenza (HPAI) virus detections in poultry, captive and wild birds that occurred in and outside Europe between 24 June and 1 September 2023, as well as HPAI virus detections in mammals (up to 15 September 2023) and human cases due to avian influenza virus (up to 14 September
2023).
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 16-22 July 2023 and includes updates on avian influenza, Echovirus 11, COVID-19, West Nile virus, poliomyelitis, and botulism.
Between 29 April and 23 June 2023, highly pathogenic avian influenza (HPAI) A(H5N1) virus (clade 2.3.4.4b) outbreaks were reported in domestic (98) and wild (634) birds across 25 countries in Europe.